MRC1 and acute myeloid leukemia: Analysing gene expression and clinical data from the Beat AML trial, Xu et al. (2019) then demonstrated that AML patients exhibiting higher CD206 expression levels had an inferior response to induction therapy compared to patients with a lower expression of CD206.